Largest biotech companies by cash on hand
Cash and cash equivalents at the end of the latest fiscal year. Short-term investments are not counted.
Amgen leads the 24 biotech companies ranked by cash on hand, at HUF 3.07T, ahead of BioNTech (HUF 2.86T) and Gilead Sciences (HUF 2.54T). Figures as of 19 Nov 2026, 02:14 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenHUF 3.07T
- Median
- HUF 145.6B
- Combined market value
- HUF 281.09T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Cash on hand ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | HUF 3.07T | HUF 80.69T | HUF 149,170.57 | 3.07% down | 34% up | ||
| 2 | BioNTechBNTX · Health Care | HUF 2.86T | HUF 6.94T | HUF 27,979.77 | 1.89% down | 16% down | ||
| 3 | Gilead SciencesGILD · Health Care | HUF 2.54T | HUF 70.43T | HUF 56,786.24 | 0.75% down | 33% up | ||
| 4 | argenxARGX · Health Care | HUF 1.17T | HUF 19.89T | HUF 316,309.89 | 0.66% down | 4% up | ||
| 5 | BiogenBIIB · Health Care | HUF 1.01T | HUF 12.49T | HUF 84,487.08 | 0.25% up | 49% up | ||
| 6 | ModernaMRNA · Health Care | HUF 872.1B | HUF 26.76T | HUF 66,131.87 | 4.84% down | 755% up | ||
| 7 | ImmunovantIMVT · Health Care | HUF 303.2B | HUF 2.31T | HUF 11,146.88 | 0.12% down | 43% up | ||
| 8 | QiagenQGEN · Health Care | HUF 282B | HUF 3.44T | HUF 16,654.79 | 0.38% down | 12% up | ||
| 9 | Neurocrine BiosciencesNBIX · Health Care | HUF 239.6B | HUF 5.54T | HUF 54,729.59 | 1.84% down | 20% up | ||
| 10 | RepligenRGEN · Health Care | HUF 190.2B | HUF 3.71T | HUF 58,026.27 | 6.47% up | 5% up | ||
| 11 | Krystal BiotechKRYS · Health Care | HUF 166.8B | HUF 3.14T | HUF 105,970.95 | 5.62% up | 46% up | ||
| 12 | ExelixisEXEL · Health Care | HUF 162.1B | HUF 5.6T | HUF 22,949.06 | 0.31% down | 63% up | ||
| 13 | Revolution MedicinesRVMD · Health Care | HUF 129B | HUF 11.62T | HUF 53,707.99 | 1.76% down | 131% up | ||
| 14 | Kymera TherapeuticsKYMR · Health Care | HUF 120B | HUF 3.48T | HUF 40,706.10 | 0.32% down | 87% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | HUF 116.8B | HUF 1.31T | HUF 13,505.97 | 0.10% up | 21% down | ||
| 16 | Scholar Rock HoldingSRRK · Health Care | HUF 108.7B | HUF 1.97T | HUF 16,130.54 | 6.48% up | 14% up | ||
| 17 | Bio-TechneTECH · Health Care | HUF 89B | HUF 3.84T | HUF 24,447.86 | 0.17% up | 26% up | ||
| 18 | Kodiak SciencesKOD · Health Care | HUF 70.5B | HUF 2.15T | HUF 32,869.34 | 1.04% up | 396% up | ||
| 19 | Twist BioscienceTWST · Health Care | HUF 61.5B | HUF 2.67T | HUF 39,099.77 | 3.88% up | 340% up | ||
| 20 | VaxcytePCVX · Health Care | HUF 58.5B | HUF 3.11T | HUF 19,665.82 | 1.48% down | 22% up | ||
| 21 | Halozyme TherapeuticsHALO · Health Care | HUF 45B | HUF 3.67T | HUF 32,193.88 | 0.18% down | 37% up | ||
| 22 | ImmunityBioIBRX · Health Care | HUF 29.7B | HUF 2.4T | HUF 2,251.56 | 7.03% up | 193% up | ||
| 23 | Adaptive BiotechnologiesADPT · Health Care | HUF 23.7B | HUF 1.55T | HUF 9,564.07 | 0.11% down | 88% up | ||
| 24 | CG OncologyCGON · Health Care | HUF 10.9B | HUF 2.4T | HUF 26,884.24 | 1.34% up | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Cash on hand is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 336.1 HUF).
Questions and answers
Which biotech companies rank first by cash on hand?
Amgen (HUF 3.07T), BioNTech (HUF 2.86T) and Gilead Sciences (HUF 2.54T) are the top three of the 24 biotech companies ranked by cash on hand as of 19 Nov 2026, 02:14 UTC.
How many biotech companies are in this ranking?
24 are ranked by cash on hand.
What are these biotech companies worth together?
The 24 biotech companies ranked by cash on hand have a combined market value of HUF 281.09T as of 19 Nov 2026, 02:14 UTC.
What does ranking by cash on hand measure?
Cash and cash equivalents at the end of the latest fiscal year. Short-term investments are not counted.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies by cash on hand”, data as of 19 November 2026. https://funkfolio.com/companies/category/biotech?by=cash-on-hand
Underlying data: Yahoo Finance; SEC EDGAR.